Chief Scientific Officer
Nick has more than 21 years of experience in clinical development and consulting. He has been with Syneos Health since 2006 and grew and led the Oncology team until his move to CSO in 2018. He is passionate about rapidly moving compelling new science for unmet medical needs through the development process to arrive at early and innovative decisions. In his role as CSO, Nick oversees our 6-pillar Consortia model, which includes focus in Rare Diseases, Cell and Gene Therapies, Biosimilars, Pediatric, Biotech Solutions, and Combination Drug/Medical Device Products. Nick is also Syneos Health’s senior representative to the Clinical Trials Transformation Initiative (CTTI) Steering Committee. His early career was in biomedical research in the UK, US and Canada, and he was on faculty at the University of Vermont Medical School for several years.